Heads-Up Spark Therapeutics Investors: 4 Wall Street Firms Are Now Bullish
Spark Therapeutics Inc (NASDAQ: ONCE), a small-cap gene therapy developer that went public on January 30, is up more than 1.3 percent on Tuesday morning, after several major Wall Street research firms initiated coverage with positive ratings.
Related Link: What You Need To Know About The Spark Therapeutics IPO
Roth Capital assumed coverage with a Buy rating and a $71 price target.
Cowen & Company gave the stock an Outperform rating accompanied by a $65 price target.
Credit Suisse also issued an Outperform rating, and set its price target at $76.
Finally, JP Morgan initiated coverage with an Overweight rating and a $74 price target.
About Spark Therapeutics
Spark Therapeutics is a $1.36 billion market cap company that focuses on developing (one-time, life-altering) gene therapy products for patients suffering from debilitating genetic diseases. It addresses a range of debilitating genetic diseases including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases.
Latest Ratings for ONCE
Feb 2015 | Credit Suisse | Initiates Coverage on | Outperform | |
Feb 2015 | JP Morgan | Initiates Coverage on | Overweight | |
Feb 2015 | Cowen & Company | Initiates Coverage on | Outperform |
View More Analyst Ratings for ONCE
View the Latest Analyst Ratings
See more from Benzinga
Technology Disruptors And The Future Of The Internet: Cantor Provides Some Ideas For 2015
Wedbush Previews Foundation Medicine, Expects In-Line Earnings
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
